APQ Health

APQ Health develops FDA-cleared AI-powered software for automated quantitative analysis of 3D medical images, specializing in coronary plaque analysis from CT angiography. The company's flagship product, Autoplaque, provides deep learning–enabled quantification of coronary atherosclerosis, plaque characterization, and stenosis assessment. Backed by over 100 peer-reviewed publications and validation across 35 academic sites, including the landmark SCOT-HEART multicenter trial, Autoplaque demonstrates 95% agreement with invasive IVUS and ICC 0.95 correlation with expert readers. The software enables clinicians to quantify total plaque volume, identify low-attenuation (vulnerable) plaque burden, and predict patient-specific myocardial infarction risk. APQ Health's solution integrates clinical decision support with evidence-driven insights to improve cardiac risk stratification and patient outcomes.